Evaluation of Kidney Damage Using NGAL Measurements

Launched by ANKARA CITY HOSPITAL BILKENT · Feb 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to measure kidney function in men undergoing robotic surgery for prostate issues. The researchers want to see if measuring a specific substance in the blood called NGAL (Neutrophil Gelatinase-Associated Lipocalin) can help detect kidney damage earlier and more accurately than the standard tests currently used, which are called sCr (serum creatinine) and BUN (blood urea nitrogen).

To take part in this study, participants need to be men aged between 18 and 80 years who are generally healthy, with certain health ratings (ASA scores 1-2). The trial is taking place at Ankara City Hospital in Turkey, and they're looking for a total of 55 participants. Those who have existing kidney problems, cannot understand or sign a consent form, or choose not to participate will not be included. If eligible, participants can expect to have their NGAL levels measured along with the standard kidney tests during their surgery, helping researchers understand how effective this new measurement can be for monitoring kidney health.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • A total of 55 patients, with ASA scores 1-2-3, aged between 18 and 80 years, will be included in the study conducted at the Robotic Surgery operating room of Ankara City Hospital, Ministry of Health, Turkey.
• Exclusion Criteria:
• • -1. Individuals who do not have the ability to read, understand, or sign the consent form.
• • 2. Individuals with diagnosed renal disease. 3. Patients who do not wish to participate in the study. 4. Patients classified as ASA-3 or higher.